Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan J Mathis

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|February 6, 2023
Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumorsShotaro Sakka, Shuya Kandori, Koji Kawai, et al.
BMC Urology|December 26, 2025
Three-dimensional image reconstruction technology in laparoscopic pyeloplasty for horseshoe kidney-associated ureteropelvic junction obstruction: a case series studyShuya Kandori, Kosuke Kojo, Akio Hoshi, et al.
International Journal of Molecular Sciences|July 13, 2024
<i>TNFSF9</i> Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and IpilimumabBunpei Isoda, Shuya Kandori, Tomokazu Sazuka, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2026
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based CombinationsHiromichi Sakurai, Masanobu Shiga, Shuya Kandori, et al.
Frontiers in Oncology|January 10, 2022
Case Report: Molecular Characterization of Aggressive Malignant Retroperitoneal Solitary Fibrous Tumor: A Case StudyHaruna Nonaka, Shuya Kandori, Satoshi Nitta, et al.
Scientific Reports|August 21, 2025
A novel, synthesized, amphiphilic ethylene glycol squalene derivative suppresses BBN-induced bladder carcinogenesisKeisuke Sano, Masanobu Shiga, Farhana Ferdousi, et al.
Oncology Reports|November 29, 2021
ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinomaKen Tanaka, Shuya Kandori, Shotaro Sakka, et al.
BMJ Open|December 12, 2025
Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocolHaruka Negishi, Koji Hirata, Hitoshi Aiyama, et al.
Cancer Research Communications|September 5, 2025
Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerBunpei Isoda, Masanobu Shiga, Shuya Kandori, et al.
Scientific Reports|April 23, 2026
Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumabSatoka Kinase, Yoshiyuki Nagumo, Bunpei Isoda, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
International Journal of Urology : Official Journal of the Japanese Urological Association|February 6, 2023
Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumorsShotaro Sakka, Shuya Kandori, Koji Kawai, et al.
BMC Urology|December 26, 2025
Three-dimensional image reconstruction technology in laparoscopic pyeloplasty for horseshoe kidney-associated ureteropelvic junction obstruction: a case series studyShuya Kandori, Kosuke Kojo, Akio Hoshi, et al.
International Journal of Molecular Sciences|July 13, 2024
<i>TNFSF9</i> Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and IpilimumabBunpei Isoda, Shuya Kandori, Tomokazu Sazuka, et al.
Cancer Reports (Hoboken, N.J.)|June 17, 2026
Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based CombinationsHiromichi Sakurai, Masanobu Shiga, Shuya Kandori, et al.
Frontiers in Oncology|January 10, 2022
Case Report: Molecular Characterization of Aggressive Malignant Retroperitoneal Solitary Fibrous Tumor: A Case StudyHaruna Nonaka, Shuya Kandori, Satoshi Nitta, et al.
Scientific Reports|August 21, 2025
A novel, synthesized, amphiphilic ethylene glycol squalene derivative suppresses BBN-induced bladder carcinogenesisKeisuke Sano, Masanobu Shiga, Farhana Ferdousi, et al.
Oncology Reports|November 29, 2021
ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinomaKen Tanaka, Shuya Kandori, Shotaro Sakka, et al.
BMJ Open|December 12, 2025
Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocolHaruka Negishi, Koji Hirata, Hitoshi Aiyama, et al.
Cancer Research Communications|September 5, 2025
Prognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancerBunpei Isoda, Masanobu Shiga, Shuya Kandori, et al.
Scientific Reports|April 23, 2026
Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumabSatoka Kinase, Yoshiyuki Nagumo, Bunpei Isoda, et al.
Pageof 15